FDA
-
-
-
-
-
-
-
Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE
-
-
-
-
-
-
-
Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
-
-
-
-
-
-
-
Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry
-
-
-
-
-
-
-
Allurion Technologies (ALUR) Announces $2.5M Share Placement, Reports Prelim Q4 Results
-
-
-
-
-
-
-
Allurion Technologies (ALUR) Closes $48M Convertible Senior Secured Note Financing
-
-
-
-
-
-
322,897 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

